ORPHA:521
Chronic myeloid leukemia
Also known as: CML · Chronic granulocytic leukemia · Chronic myelogenous leukemia
Publications
83,853
99.7th percentile
Trials
793
Interventional, condition-specific
Researchers
1,285
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Chronic myeloid leukaemia (CML) is the most common myeloproliferative disorder accounting for 15-20% of all leukaemia cases.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011996
- OMIM:608232
- UMLS:C0279543
- NCIT:C3174
Additional Mondo synonyms (17)
BCR-ABL Positive chronic myelogenous leukaemia · BCR-ABL Positive chronic myelogenous leukemia · CML - chronic myelogenous leukaemia · CML - chronic myelogenous leukemia · chronic granulocytic leukemia · chronic myelocytic leukaemia · chronic myelocytic leukemia · chronic myelogenous leukaemia (CML) · chronic myelogenous leukemia · chronic myelogenous leukemia (CML) · chronic myelogenous leukemia, BCR-ABL1 Positive · chronic myelogenous leukemias · chronic myeloid leukemia · hematopoeitic - chronic myelocytic leukaemia (CML) · hematopoeitic - chronic myelocytic leukemia (CML) · leukimia, chronic myeloid · myeloid leukemia, chronic
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
83,853 matched papers (39,907 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
793 matched on ClinicalTrials.gov (77 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
83,853
83,853 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
83,853 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
39,907 in the last 10 years · medium confidence · 99.7th percentile (publications denominator)
Phrase hits: 83,853 · MeSH hits: 0
Who's working on it?
1,285
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhang Y11 papers · 2026
Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Henan, China.
Papers in Europe PMC - 02Takahashi N8 papers · 2026
Department of Hematology, Akita University Hospital, 1-1-1 Hondo, Akita City, Akita, 010-8543, Japan. naotot@doc.med.akita-u.ac.jp.
Papers in Europe PMC - 03Breccia M6 papers · 2026
Dept of Translational and Precision Medicine, Sapienza University-Az, Policlinico Umberto, Rome, Italy. Electronic address: breccia@bce.uniroma1.it.
Papers in Europe PMC - 04Liu Z6 papers · 2026
Department of Hematology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China.
Papers in Europe PMC - 05Iqbal Z5 papers · 2026
College of Applied Medical Sciences (CoAMS) , King Saud Bin Abdulaziz University of Health Sciences, Riyadh, Saudi Arabia.
Papers in Europe PMC - 06Abdulgayoom M4 papers · 2026
Hematology Department, National Center for Cancer Care and Research (NCCCR), Doha 3050, Qatar.
Papers in Europe PMC - 07Chen C4 papers · 2026
Department of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Papers in Europe PMC - 08Cortes JE4 papers · 2026
Georgia Cancer Center at Augusta University, Augusta, GA. jorge.cortes@augusta.edu.
Papers in Europe PMC - 09Jiang Q4 papers · 2026
National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China; Department of Hematology, peking University People's Hospital, Qingdao, China. Electronic address: jiangqian@medmail.com.cn.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
793
interventional trials for this specific condition
793 interventional trials matched this specific condition name; 77 currently recruiting in our sample. 2,246 trials are registered for myeloid leukemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
793 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.8th percentile).
medium confidence · 99.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
793 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT02727803·RECRUITING·Personalized NK Cell Therapy in CBT
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia in Remission·Matched via name phrase
- NCT06401603·RECRUITING·A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Conditions: Advanced Chronic Myeloid Leukemia · Philadelphia Chromosome-Positive Acute Myeloid Leukemia·Matched via name phrase
- NCT05549661·RECRUITING·Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Conditions: Recurrent Chronic Myelomonocytic Leukemia · Refractory Chronic Myelomonocytic Leukemia · Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified · Recurrent Atypical Chronic Myeloid Leukemia·Matched via name phrase
- NCT06013423·RECRUITING·Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Conditions: Acute Leukemia of Ambiguous Lineage · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Blastic Plasmacytoid Dendritic Cell Neoplasm·Matched via name phrase
- NCT04888741·RECRUITING·Methods of T Cell Depletion Trial (MoTD)
Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndromes·Matched via name phrase
- NCT07710781·NOT YET RECRUITING·Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Conditions: Hematologic Malignancy · Acute Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia·Matched via name phrase
- NCT05130138·RECRUITING·Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia
Conditions: Chronic Myeloid Leukemia·Matched via name phrase
- NCT07493408·NOT YET RECRUITING·Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
Conditions: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) · Blastic Transformation of Chronic Myeloid Leukemia · Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL) · Haematopoietic Stem Cell Transplant, Allogeneic·Matched via name phrase
- NCT05884333·RECRUITING·Cord Blood Transplant in Adults With Blood Cancers
Conditions: Acute Myelogenous Leukemia (AML) · Acute Lymphoblastic Leukemia (ALL) · Chronic Myelogenous Leukemia (CML) · Myelodysplastic Syndromes (MDS)·Matched via name phrase
- NCT03326310·RECRUITING·Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Conditions: Chronic Myeloid Leukemia · Myelofibroses·Matched via name phrase
- NCT06398457·RECRUITING·Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Conditions: Hematologic Malignancy · Bone Marrow Transplant Rejection · Acute Myeloid Leukemia (AML) · Myelodysplastic Syndromes (MDS)·Matched via name phrase
- NCT03314974·RECRUITING·Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Conditions: Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Lymphoma·Matched via name phrase
- NCT05794880·RECRUITING·MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Conditions: Leukemia · Acute Myeloid Leukemia in Remission · Myelodysplasia · Acute Lymphoblastic Leukemia in Remission·Matched via name phrase
- NCT06453902·RECRUITING·TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Conditions: Chronic Myeloid Leukemia · Accelerated Phase CML·Matched via name phrase
- NCT03589729·RECRUITING·Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Conditions: Acute Myeloid Leukemia · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blasts 10 Percent or More of Bone Marrow Nucleated Cells · High Risk Myelodysplastic Syndrome·Matched via name phrase
Broader category: myeloid leukemia
2,246
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT00801489·RECRUITING·Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 · Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 · de Novo Myelodysplastic Syndrome·Matched via name phrase
- NCT06904066·RECRUITING·Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Conditions: Malignancy, Hematologic · Neoplasms, Hematologic · Neoplasms, Hematopoietic · Blood Cancer·Matched via name phrase
- NCT06345365·RECRUITING·MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukaemia·Matched via name phrase
- NCT07198867·RECRUITING·A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia (AML) · CAR-T Cell Therapy·Matched via name phrase
- NCT03300492·RECRUITING·Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
Conditions: Acute Myeloid Leukemia · Myelodysplastic Syndromes·Matched via name phrase
- NCT07356154·RECRUITING·A Study of Revumenib and Mezigdomide in People With Leukemia
Conditions: Leukemia · Acute Leukemia · Relapse Leukemia · Refractory Leukemia·Matched via name phrase
- NCT07521124·NOT YET RECRUITING·ABC Maintenance Therapy for AML
Conditions: Acute Myeloid Leukemia (AML) in Remission·Matched via name phrase
- NCT05949125·RECRUITING·Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
Conditions: Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory·Matched via name phrase
- NCT07025824·NOT YET RECRUITING·Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Conditions: AML - Acute Myeloid Leukemia · MDS (Myelodysplastic Syndrome)·Matched via name phrase
- NCT05991908·RECRUITING·Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Conditions: Acute Myeloid Leukemia · Myelodysplastic Syndromes·Matched via name phrase
- NCT04869683·RECRUITING·Biocollection in MyeloDysplastic Syndrome (P-MDS)
Conditions: Myelodysplastic Syndromes · Myelodysplastic Anemia · Myelodysplastic Syndrome With Isolated Del(5Q) · Myelodysplastic Syndrome With Ring Sideroblasts·Matched via name phrase
- NCT07082452·NOT YET RECRUITING·A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
Conditions: Leukemia, B-Cell, Chronic · Leukemia·Matched via name phrase
- NCT06297941·RECRUITING·Study of REM-422 in Patients With AML or Higher Risk MDS
Conditions: Myelodysplastic Syndromes · Higher Risk Myelodysplastic Syndromes · Acute Myeloid Leukemia · Acute Myeloid Leukemia Refractory·Matched via name phrase
- NCT07366801·RECRUITING·Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Conditions: Acute Myeloid Leukemia, Relapsed · Acute Lymphoblastic Leukemia, High Risk · Acute Myeloid Leukemia, High Risk · Acute Lymphoblastic Leukemia, Relapse·Matched via name phrase
- NCT07575412·NOT YET RECRUITING·SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · MDS · Transplantation, Stem Cell·Matched via name phrase
Observational and natural-history studies
152 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07165535·RECRUITING·Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network
Conditions: Chronic Myeloid Leukemia (CML)·Matched via name phrase
- NCT07681258·NOT YET RECRUITING·A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
Conditions: Chronic Myeloid Leukemia·Matched via name phrase
- NCT06865443·NOT YET RECRUITING·Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia
Conditions: Chronic Myeloid Leukemia (CML)·Matched via name phrase
- NCT05963061·RECRUITING·Chronic Myeloid Leukemia (CML) Real-Life Database
Conditions: Chronic Myeloid Leukemia (CML)·Matched via name phrase
- NCT05282108·RECRUITING·Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Conditions: Chronic Myeloid Leukemia·Matched via name phrase
- NCT05334069·RECRUITING·Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Conditions: Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Ann Arbor Stage I Lymphoma · Ann Arbor Stage II Lymphoma·Matched via name phrase
- NCT05440747·NOT YET RECRUITING·Treatment Free Remission (TFR) in CML Patients (CML-CP)Study
Conditions: Chronic Myeloid Leukemia · Treatment-free Remission·Matched via name phrase
- NCT05605379·RECRUITING·CML Pediatric ITK Response According to Molecular Identification at Diagnosis
Conditions: Chronic Myeloid Leukemia·Matched via name phrase
- NCT01890486·RECRUITING·The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Conditions: Acute Myelogenous Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia · Non-Hodgkin's Lymphoma·Matched via name phrase
- NCT01351545·RECRUITING·A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies · Inherited Disorders of Metabolism · Inherited Abnormalities of Platelets · Histiocytic Disorders·Matched via name phrase
- NCT06297161·RECRUITING·A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
Conditions: Chronic Leukemia Myelogenous·Matched via name phrase
- NCT07061145·RECRUITING·A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
Conditions: Chronic Myelocytic Leukemia · Erectile Dysfunctions · CVD - Cardiovascular Disease · Tyrosine Kinase Inhibitor·Matched via name phrase
- NCT07640750·NOT YET RECRUITING·Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines
Conditions: Chronic Myeloid Leukemia · Chronic Myeloid Leukemia - Chronic Phase·Matched via name phrase
- NCT04769947·RECRUITING·Italian Treatment Free Remission Registry
Conditions: Treatment Free Remission · Chronic Myeloid Leukemia·Matched via name phrase
- NCT06665412·RECRUITING·Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
Conditions: Chronic Phase Ph+ Chronic Myeloid Leukemia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Chronic myeloid leukemia" OR "Chronic granulocytic leukemia" OR "Chronic myelogenous leukemia" OR "BCR-ABL Positive chronic myelogenous leukaemia" OR "BCR-ABL Positive chronic myelogenous leukemia" OR "CML - chronic myelogenous leukaemia" OR "CML - chronic myelogenous leukemia" OR "chronic myelocytic leukaemia" OR "chronic myelocytic leukemia" OR "chronic myelogenous leukaemia (CML)" OR "chronic myelogenous leukemia (CML)" OR "chronic myelogenous leukemia, BCR-ABL1 Positive" OR "chronic myelogenous leukemias" OR "hematopoeitic - chronic myelocytic leukaemia (CML)" OR "hematopoeitic - chronic myelocytic leukemia (CML)" OR "leukimia, chronic myeloid" OR "myeloid leukemia, chronic"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Chronic myeloid leukemia" OR "Chronic granulocytic leukemia" OR "Chronic myelogenous leukemia" OR "BCR-ABL Positive chronic myelogenous leukaemia" OR "BCR-ABL Positive chronic myelogenous leukemia" OR "CML - chronic myelogenous leukaemia" OR "CML - chronic myelogenous leukemia" OR "chronic myelocytic leukaemia" OR "chronic myelocytic leukemia" OR "chronic myelogenous leukaemia (CML)" OR "chronic myelogenous leukemia (CML)" OR "chronic myelogenous leukemia, BCR-ABL1 Positive" OR "chronic myelogenous leukemias" OR "hematopoeitic - chronic myelocytic leukaemia (CML)" OR "hematopoeitic - chronic myelocytic leukemia (CML)" OR "leukimia, chronic myeloid" OR "myeloid leukemia, chronic"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 793 interventional · 152 observational · 11 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"myeloid leukemia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: CML
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T14:10:33.328Z
